Yahoo · Oct 1, 2026
Top Midday Gainers
Nexalin Technology (NXL) signed an agreement to appoint Inovanexa Medical Technologies as its exclus
NX
NASDAQ · NXL
Nexalin Technology, Inc.
Healthcare · Medical - Devices
$4.11
Down-$0.21 (-4.86%)
Updated Oct 9, 2026, 10:24 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 18.08M
- P/E ratio
- -1.99
- Dividend yield
- 0.00%
- 52-week range
- $0.31 – $10.98
- Volume
- 428.34K
- Avg. volume
- 3.55M
Price performance · NXL
NXL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
NXL closed at $4.11 after 21 trading sessions, down 15.61% for the selected period.
- Last close
- $4.11
- Period change
- -15.61%
- Period low
- $4.11
- Period high
- $7.55
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $4.25 | $4.34 | $3.97 | $4.11 | 428.34K |
| Oct 7, 2026 | $4.38 | $4.7599 | $4.31 | $4.32 | 94.39K |
| Oct 6, 2026 | $5.23 | $5.56 | $4.50 | $4.50 | 111.8K |
| Oct 5, 2026 | $5.38 | $6.30 | $5.12 | $5.43 | 330.3K |
| Oct 2, 2026 | $5.63 | $5.95 | $5.15 | $5.73 | 1.37M |
| Oct 1, 2026 | $8.80 | $10.98 | $6.80 | $7.55 | 62.34M |
| Sep 30, 2026 | $4.4814 | $4.50 | $4.1001 | $4.28 | 7.27K |
| Sep 29, 2026 | $4.60 | $5.31 | $4.35 | $4.35 | 65.85K |
| Sep 28, 2026 | $4.50 | $4.53 | $4.10 | $4.27 | 5.71K |
| Sep 25, 2026 | $4.39 | $4.39 | $4.39 | $4.39 | 2.16K |
| Sep 24, 2026 | $4.96 | $5.0202 | $4.30 | $4.3545 | 10.23K |
| Sep 23, 2026 | $4.61 | $5.0853 | $4.61 | $4.812 | 7K |
| Sep 22, 2026 | $4.40 | $4.63 | $4.3101 | $4.63 | 13.33K |
| Sep 21, 2026 | $4.80 | $5.143 | $4.00 | $4.27 | 12.16K |
| Sep 18, 2026 | $5.0613 | $5.3599 | $4.73 | $4.90 | 14.99K |
| Sep 17, 2026 | $4.86 | $5.10 | $4.84 | $5.0992 | 8.71K |
| Sep 16, 2026 | $4.89 | $4.92 | $4.80 | $4.92 | 8.2K |
| Sep 15, 2026 | $5.08 | $5.10 | $4.80 | $4.85 | 8.21K |
| Sep 14, 2026 | $4.90 | $5.02 | $4.89 | $4.99 | 4.48K |
| Sep 11, 2026 | $4.91 | $4.97 | $4.5397 | $4.82 | 14.61K |
| Sep 10, 2026 | $4.90 | $5.13 | $4.62 | $4.87 | 57.27K |
Latest NXL news
The latest Smart Investors Daily articles mentioning NXL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NXL research
Overview
Company profile and research snapshot.
Company profile
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $4.08
- Implied upside
- —
- Analysts
- 5
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 24, 2025 | Maxim Group | Buy | — |
| Dec 5, 2024 | Maxim Group | Hold | — |
| Oct 9, 2024 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 1, 2026
Nexalin Technology Signs South America Distribution Agreement for Nexalin Sync Commercialization
The 10-year exclusive agreement covers seven countries and includes an initial binding device order, a Brazilian clinical pilot and a framework for locally manufactured devices and recurring electrode royalties. Key Investor TakeawaysNexalin Technology (NASDAQ:NXL) signed a definitive exclusive South America distribution agreement with Inovanexa Medical Technologies covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela.
Benzinga · Oct 1, 2026
Why Is Nexalin Technology Stock Gaining Thursday?
Nexalin Technology (NXL) stock surged 80% on massive volume following a 10-year South American distribution and manufacturing deal.
Yahoo · Oct 1, 2026
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers Agreement establishes a 10-year commercial framework covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, anchored by an initial 100-device commercialization program and minimum re
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
